Ann: APAS Presented at Australian Pharmaceutical Conference, page-3

Astra Zenica wouldn't have provided a million dollars to develop APAS QC ,if there wasn't a commercial rationale. I have looked at Rapid system bio,hey are selling about 5 machines per quarter, which seem to cost about 800 000,. So Lbt are a bit late to the market,but on the other hand ,why didn't Astra Zenica go with Rapid micro systems? Rapid micro have their own international sales teams ,and are losing currently about 31c per share per quarter ,but expect break even by middle of next year. 100% institutions and insider ownership, currently valued at around 60% of cash on hand. Back to LBT .There are certainly a lot of embittered lbt long time retail shareholders,but that has no bearing on the future prospects,.It has to be admitted though,that ,until now ,the negative view has been correct. Except that not taking up their rights was effectively shooting themselves in the foot. We will see, within 9 months which sentiment matches reality.